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Abstract 
Although several recent studies employing various truncated fragments of streptokinase (SK) have demonstrated that the 
high-affinity interactions of this protein with human plasminogen (HPG) to form the activator complex (SK-HPG) are 
located in the central region of SK, the exact location and nature of such HPG interacting site@) is still unclear. In order 
to locate the “core” HPG binding ability in SK, we focused on the primary structure of a tryptic fragment of SK derived 
from the central region (SK143-293) that could bind as well as activate HPG, albeit at reduced levels in comparison 
to the activity of the native, full-length protein. Because this fragment was refractory to further controlled proteolysis, 
we took recourse to a synthetic peptide approach wherein the HPG interacting properties of 16 overlapping 20-mer 
peptides derived from this region of SK were examined systematically. Only four peptides from this  set, viz., SK234- 
253,  SK254-273,  SK274-293, and SK263-282, together representing the contiguous sequence SK234-293, displayed 
HPG binding ability. This was established by a specific HPG-binding ELISA as well as by dot blot assay using 
‘251-labeled HPG. These results showed that the minimal sequence with HPG binding function resided between residues 
234 and 293. None of the synthetic SK peptides was found to activate HPG, either individually or in combination, but, 
in competition experiments where each of the peptides was added prior to complex formation between SK and HPG, 
three of the HPG binding peptides (SK234-253,  SK254-273, and SK274-293) inhibited strongly the generation of a 
functional activator complex by SK and HPG. This indicated that residues 234-293 in SK participate directly in 
intermolecular contact formation with HPG during the formation of the 1: 1 SK-HPG complex. Two of the three peptides 
(SK234-253 and SK274-293), apart from interfering in SK-HPG complex formation,  also showed inhibition of the 
amidolytic activity of free HPN by increasing the K, by approximately fivefold. A similar increase in K, for amidolysis 
by HPN as a result of complexation with SK has been interpreted previously to arise from the steric hinderance at or 
near the active site  due to the binding of SK in this region. Thus,  our results suggest that SK234-253 and SK274-293 
also, like SK, bound close to the active site of HPN, an event that was reflected in the observed alteration in its substrate 
accessibility. By contrast, whereas the intervening peptide (SK254-273) could not inhibit amidolysis by free HPN, it 
showed a marked inhibition of the activation of “substrate” PC (human or bovine plasminogen) by activator complex, 
indicating that this particular region is intimately involved in interaction of the SK-HPG activator complex with 
substrate plasminogen during the catalytic cycle. This finding provides a rational explanation for one of the most 
intriguing aspects of SK action, Le., the ability of the SK-HPG complex to catalyze selectively the activation of substrate 
molecules of PC to PN, whereas free HPN alone cannot do so. Taken together, the results presented in this paper strongly 
support a model of SK action in which the segment 234-293 of SK, by virtue of the epitopes present in residues 
234-253 and 274-293, binds close to the active center of HPN (or, a cryptic active site, in the case of HPG) during the 
intermolecular association of the two proteins to form the equimolar activator complex; the segment SK254-273 present 
in the center of the core region then imparts an ability to the activator complex to interact selectively with substrate PC 
molecules during each PC activation cycle. 
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peptides 
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Streptokinase is a secretory protein of 414 residues produced by 
selected species of the  genus Streptococcus that is used often  as a 
thrombolytic drug for the treatment of several circulatory disor- 
ders, including myocardial infarction (ISIS-3, 1992), wherein it 
has been demonstrated to be virtually as efficacious as its more 
expensive alternatives, namely UK and TPA. In contrast to UK and 
TPA, relatively much less is known of the structural basis for  the 
biochemical action of SK. This protein, which has been studied by 
CD, Raman, and IR spectroscopies, as well as by NMR at rela- 
tively low resolution, has been shown to possess at least three 
flexible  domains  (Radek & Castellino, 1989; Fabian et al., 1992; 
Misselwitz et al., 1992; Welfle et al., 1992; Teuten et al., 1993). 
Detailed three-dimensional information on SK, such as by high- 
resolution NMR or X-ray diffraction, is not yet available. How- 
ever, at least at the biochemical level, its mechanism of action has 
been the subject of detailed investigations (reviewed in Castellino, 
1981). A fundamental difference between SK, on the one hand, and 
UK and TPA, on the other, lies in  the fact that, unlike the latter two, 
which possess intrinsic protease activity and, hence, directly act as 
HPG activators, SK is an “indirect” HPG activator. SK possesses 
no enzymatic activity of its own, but forms an enzymatically ac- 
tive, stoichiometric, noncovalent complex with either HPG or HPN, 
which then activates other “substrate” molecules of PG to PN by 
selective cleavage of the ATg560-Va1561 peptide bond (Markus & 
Werkheiser, 1964; McClintock & Bell, 197 1; Reddy & Markus, 
1972). There  is now a compelling need to understand the structural 
basis of SK action in greater detail in order to engineer therapeu- 
tically improved SK derivatives (Marder, 1993). 
In the past, most attempts at elucidating structure-activity rela- 
tionships in SK have centered chiefly on examining the HPG ac- 
tivating and/or binding properties of truncated fragments after 
proteolysis of the native protein, or expression of SK genes car- 
rying defined deletions (Siefring & Castellino, 1976; Malke et al., 
1987; Rodriguez et al., 1994, 1995; Shi et al., 1994; Nihalani & 
Sahni, 1995; Reed et al., 1995; Young et al., 1995; Parrado et al., 
1996). These studies collectively have revealed that progressive 
deletions  from  either the C- or N-termini of SK beyond roughly 
30-40 residues drastically compromise the HPG activation prop- 
erty of the molecule. By contrast, the relatively more “primal” 
property of HPG binding is preserved even in relatively short 
polypeptide fragments derived from SK. In the recent past, the 
binding of HPG has been demonstrated with different truncated 
fragments of SK viz., SKI-253 (Reed et al., 1993). SK60-233 
(Shi et al., 1994), SK120-352, SK244-352 (Reed et al., 1995), 
SK143-293 (Rodriguez et al., 1994; Nihalani & Sahni, 1995), 
SK220-414 (Young et al., 1995),  SK64-380 and SK147-380 (Par- 
rad0  et al., 1996). So far, the smallest independently HPG activat- 
ing SK fragments have been shown to be 147-380 (Parrado  et al., 
1996) and 143-293 (Rodriguez et al., 1994; Nihalani & Sahni, 
1995). Even though these studies, taken together, do successfully 
narrow down the overall length of the sequence to be examined 
from the 414 residues of the full-length native polypeptide to roughly 
the central 150-200 residues, they do not readily permit one to 
either identify conclusively the minimal-length sequence(s) in- 
volved in interaction with HPG  (nor the exact boundaries of such 
sites, if indeed multiple sites exist), or cross-correlate these “pri- 
mal” HPG binding functions with the “higher” HPG modulation 
functions. This is an issue of central importance in designing mu- 
tants of SK with altered HPG  interacting properties. Recently, we 
have reported the  presence of two independent high-affinity HPG 
binding sites in SK (Nihalani & Sahni, 1995). One, detected in an 
N-terminal fragment (residues 1-59), could be further localized to 
residues 37-51 by secondary proteolysis. The other binding site 
has been shown to lie  inside  the central portion of the molecule, 
spanning approximately 150 residues; the binding site(s) in this 
“core” region could not be narrowed down by further fragmenta- 
tion due to its refractoriness to several proteases (Misselwitz  et al., 
1992; Rodriguez et al., 1994,  1995). We therefore decided to iden- 
tify the core  HPG binding region, or regions, resident within this 
central portion of the SK polypeptide by taking recourse to a 
synthetic peptide approach (“peptide walking”), wherein a battery 
of short overlapping peptides of defined sequence, together span- 
ning the region of interest, were investigated for their ability to 
interact with HPG  as evidenced by direct binding experiments, and 
indirectly, by their ability to inhibit productive complex formation 
between SK and HPG. “Peptide walking” is a relatively recent 
approach (Joseph & Pick, 1995) that offers a complementary op- 
tion to conventional recombinant DNA-based site-directed muta- 
genic and deletion techniques for the detection and identification 
of regions of primary structure involved in protein-protein or 
protein-ligand interactions. In this communication, we report the 
identity of the minimal SK sequence(s) necessary in the binding 
site for HPG that is located in the central region of the protein. We 
also show that synthetic peptide fragments derived from this “core” 
sequence (about 50-60 residues) competitively inhibit the func- 
tionally productive interaction of SK with HPG. In addition, our 
results suggest that, by binding in the immediate vicinity of the 
active site in HPG/HPN, a part of this core region is able to impart 
the characteristic substrate PG recognition ability to the activator 
complex. 
Results 
Limited proteolysis of SK by trypsin produces three major HPG- 
binding fragments viz., SK  1-59,  SK60-293, and SK143-293 (Ni- 
halani & Sahni, 1995). In order to examine whether these possessed 
any activator activity, each fragment, after purification, was sub- 
jected to standard SK assays for measuring the activation of HPG 
to HPN. To examine even very low activities accurately, relatively 
high molar concentrations of the fragments were employed in the 
assays, and the activation reactions were followed over a relatively 
extended period of time (see Materials and methods for details). 
Although SKI-59 alone did not possess any detectable HPG- 
activating ability, fragments SK143-293 and SK60-293 showed 
low, albeit clearly detectable HPG activator activities (data not 
shown). Moreover, the HPG activating ability of these fragments 
could be enhanced significantly in the presence of SKI-59 in a 
dose-dependent manner. The activator activity of SK under these 
conditions, however, was unaffected by the presence of SK1-59 
(up to several hundred-fold molar excess over SK), indicating that 
the low activities of SK fragments (SK60-293 and SK143-293) 
are their intrinsic activities and not due to small amounts of con- 
taminating SK. Similar observations with proteolytic fragments of 
SK have also been made by other workers previously (Shi et al., 
1994; Parrado et  al., 1996). Our results with the presence of HPG 
activating ability and its augmentation by SKI-59 in SK60-293 
and SK143-293 show clearly that the “core” residues in SK par- 
ticipating with HPG in the formation of a HPG activator site are 
resident in the region 143-293 of the protein (the sequence com- 
mon to SK60-293 and SK143-293). 
In order to narrow down a minimum-length sequence in the 
smaller of the two SK fragments capable of SK binding and acti- 
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vation (SK143-293), we synthesized a series of 16 overlapping 
peptides,  each of 20 residues,  altogether  encompassing the entire 
sequence  between  residues 134 and 302 of SK. The HPG  binding 
ability  of each  peptide  was then checked  qualitatively by a  highly 
sensitive  dot blot method  involving  immobilization onto nitrocel- 
lulose membranes  followed by probing  with  '251-radiolabeled HPG. 
In parallel, the  binding  isotherms of  the peptides  were  determined 
by a quantitative ELISA developed  especially  for  HPG binding of 
SK fragments  (Nihalani & Sahni. 1995). The  results of these  bind- 
ing  experiments  are  presented in Figure 1 A and B and Table 1. The 
dot  blots reveal  that, of the 16 peptides  screened,  only 4 possessed 
detectable  binding with HPG;  this  was  also  confirmed by the re- 
sults of the ELISA, wherein only the same 4 peptides showing 
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Fig. 1. Plasminogen  hinding  analyses  of  synthetic  peptides hy dot blot and 
ELISA. A: Dot blots showing  binding of radiolabeled HPG to SK peptides. 
Positions marked I and 2 correspond to SK ( I pg)  and SK143-293 ( 5  pg). 
respectively. whereas 7. 8. 12. and I6 represent SK234-253. SK2.54-273. 
SK274-293. and SK263-282, respectively. R: Quantitative ELISA for HPG 
hinding. Plots show binding of either SK (closed  circles)  or SK peptides 
viz., SK234-253 (open inverted triangles), SK254-273 (closed  triangles). 
SK274-293 (closed squares). and SK263-282 (open  squares). with HPG. 
Control reaction where SK or SK-peptides were omitted is depicted with 
open triangles. 
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Table 1. Relative affinities of SK peptides for HPG 
Apparent dissociation constant with HPG" 
SK Peptide (mol/L) 
SK (native) 4.8 t 0.4 x 1 0 " '  
SK60-293 5.0 -c 0.5 x I O  ' 
SK143-293 4.0 2 0.7 X I O  ' 
SK234-253 4.0 5 0.8 x IO" 
SK2.54-273 s.0 2 0.2 x 10" 
SK274-293 4.5 5 0.3 x I O  
SK263-282 1.9 t 0.5 X IO- '  
SK243-262' - 
SK223-242 ND' 
SK283-302 ND 
3Values were computed through analysis of noncompetitive ELISA curves 
as  described in Materials and methods. and are means of four independent 
experiments. 
hInsolubility of this peptide  under  assay  conditions precluded determi- 
nation of HPG hinding ahility. 
'ND. HPG hinding could not he detected. 
positive  HPG  binding by dot  blot (SK234-253, SK254-273, 
SK274-293, and SK263-282) were found to interact with HPG 
(Fig. 1 B). The  HPG reactivity  of one of the  peptides (SK243-262). 
with  a sequence  overlap with  that of the other  four peptides  with 
detectable HPG binding ability, could not be studied further be- 
cause of its very low  solubility at neutral pH. The  apparent disso- 
ciation  constants of  the peptides  for  HPG  were  determined through 
analyses of  the noncompetetive ELISA curves  (Beatty  et al., 1987; 
Nihalani & Sahni, 1995). and are shown in Table I .  For compar- 
ison, the relative affinities of SK and SK143-293, determined in 
parallel, are  also provided. From these data. it was clear that the 
region 234-293 in SK (the native sequence representing the pep- 
tides showing positive HPG binding) encompasses a site for in-  
teraction  with HPG. It should  be noted that the  apparent  affinities 
of these  peptides  for  HPG are  generally 2-3 orders lower in com- 
parison to the  affinity  of SK143-293, their "parent" sequence. The 
affinity  of  the  latter for  HPG, in turn. is much  lower  compared with 
that of SK. Thus,  there  was a progressive loss in the  HPG  affinity 
of SK upon truncation of the full-length native protein to, first, 
SK60-293 and SK143-293, and. subsequently, to even shorter 
fragments. Such a decrease in HPG binding by truncation of SK 
has been shown previously also  (Rodriguez  et al., 1995) and likely 
is related to decreasing conformational stability of the resulting 
fragments. 
We next examined the ability of the short, HPG-binding pep- 
tides to activate HPG. The synthetic peptides derived from the 
region SK234-293 viz., SK234-253, SK254-273. SK274-293. 
and SK263-282, were pre-incubated individually with HPG, and 
the appearance of HPN (amidolytic) activity was then determined 
periodically (see  Materials and methods).  Whereas the  activity of 
both SK and SK143-293 could be determined  easily by this method. 
no activator activity was  detectable  even at several  thousand-fold 
molar excess of each peptide over that of HPG when tested for 
relatively extended durations (2-3 h). Similar assays performed 
with equimolar mixtures of all three contiguous peptides viz.. 
SK234-253,  SK254-273, and SK274-293, at up to several hundred- 
fold molar  excess of each  over  HPG  also failed  to show the  gen- 
eration of any  detectable plasmin  activity (data not shown). 
Streptokinase-plasminogen interactions 
The identification of peptides that demonstrated positive bind- 
ing to HPG without any detectable HPG-activating ability raised 
the question whether they would be able to inhibit the formation of 
an active complex between HPG and SK. In order to test this, the 
generation of amidolytic activity by an equimolar mixture of SK 
and HPG was conducted in the absence or presence of varying 
amounts of the HPG binding peptides. Controls where the effect of 
the peptides were evaluated on pre-formed SK-HPG complexes 
were also included. Apart from the  HPG binding peptides, we also 
tested the other 12 peptides not showing overt HPG binding by dot 
blot and ELISA. The results demonstrated that only SK234-253, 
SK254-273, and SK274-293 could inhibit the activation of HPG 
to HPN by SK in a dose-dependent manner (representative data 
from one such experiment showing the inhibition observed with 
SK234-253 is depicted in Fig. 2). In the case of SK234-253, 
SK254-273, and SK274-293, approximately 50% inhibition was 
observed in the range of 40-100 pM of peptide (Table 2). It was 
significant that the inhibition was not observed when the peptides 
were added into reactions where SK and HPG had been pre- 
incubated together, thereby demonstrating that the intermolecular 
complexation of the  two proteins was being inhibited by the pep- 
tides rather than the amidolytic activity of the complex per se. A 
synthetic peptide corresponding to SK37-51, which has been shown 
to possess independent HPG binding ability (Nihalani & Sahni, 
1995), was also tested in the inhibition assay, and found to be 
ineffective up to the highest concentration of 300 pM tried (data 
not shown). Equimolar combinations of two or more contiguous 
peptides simultaneously (up to a maximum of three peptides at one 
time) were  also tried, but a synergistic influence was not observed 
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Fig. 2. Inhibition of SK-HPG activator complex formation by SK pep- 
tides. The peptide SK234-253, derived from the core HPG binding region 
of SK, was pre-incubated at different concentrations with constant amounts 
of HPG (8 nM), and the mixtures were then assayed for generation of 
amidolytic activity in the presence of SK (10 nM). Closed circles, no 
peptide added; closed triangles, 20 pM; open inverted triangles, 40 pM;  
open squares, 80 FM; closed squares, 300 pM. A control containing all 
components except SK/SK-peptide  is depicted with open triangles. Essen- 
tially identical inhibition curves were obtained with the peptides SK254- 
273 and SK274-293. 
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Table 2. Inhibition of activator complex formation 
of SK and HPG by SK peptides 
Concentrationb corresponding 
to 50% inhibition 
Samplea (M) 
SK143-293 1.50 t 0.5 X 10" 
83234-253 3.75 2 0.6 x 10-5 
SK254-213 1.00 2 0.2 X 10-4 
SK214-293 1.10 0.3 X 10-4 
aAll 16 synthetic SK peptides, as also the fragment SK143-293, were 
screened for the inhibition of activator complex formation by SK and HPG, 
up to a maximum concentration of 300 pM. Only the three SK peptides, 
shown above, were found to inhibit the activation of HPG by SK (see text 
for details). 
bCorresponds to the concentration of peptide that caused 50% inhibition 
in the rate of a standard reaction containing equimolar amounts of SK and 
HPG. The values reported are the means of four independent experiments. 
(data not shown). In conclusion, the results with the synthetic 
peptides indicated that the sequence 234-293 in SK represents the 
primary site of high-affinity contact with HPG during activator 
complex formation. 
Even though the synthetic peptides derived from the HPG bind- 
ing  site in SK143-293 were unable, unlike the parent contiguous 
fragment, to activate the zymogen (HPG) independently to its 
active form (HPN), it was of interest to examine if these short 
peptides could alter or modulate the proteolytic specificity of the 
pre-formed active site of HPN. The binding of SK with HPN 
results in the alteration of its substrate specificity, which can be 
tested experimentally, especially by the ability of SK-HPN to ac- 
tivate BPG; neither free HPN nor SK alone are able to activate 
BPG directly, but, once SK combines with either HPN or HPG, the 
complex is able to activate BPG. To test whether even a small 
proportion of this native-like property of SK was present in any of 
the synthetic peptides, we incubated these with HPN at up to 
several hundred molar excess and then measured the ability of 
these mixtures to activate BPG. Although SK143-293 and HPN 
together could activate BPG slowly, in the case of the short pep- 
tides, even after 24 h of incubation, no BPG activation could be 
observed (data not shown). Interestingly, in the control reactions 
where BPG  was not added, it was observed that two of the peptides 
viz., SK234-253 and SK274-293, caused marked inhibition of the 
basal amidolytic activity of HPN in a concentration-dependent 
manner. This property was then tested systematically with all of 
the synthetic peptides, including ones with overt HPG binding 
ability. The results (Fig. 3A) showed a strong inhibition of plasmin 
activity by two peptides viz., SK234-253 and SK274-293. How- 
ever, the intervening segment, SK254-273, which had shown an 
ability to bind with HPG by dot blot and ELISA as well as inhibit 
the complexation of SK and HPG, did not display any inhibition of 
the amidolytic activity of free HPN. It is known that the kinetic 
parameters for amidolysis by plasmin are altered upon complex- 
ation with SK, and this has been interpreted to result from the 
binding of SK in the close vicinity of the protease active site 
(Robbins  et  al., 1981; Wohl, 1984). With this possibility in mind, 
we investigated if such an alteration in the steady-state kinetic 
parameters could be contributing to the observed inhibition of the 
amidolytic activity of HPN by the two peptides. The results 
(Fig. 3B) showed clearly that, in the presence of either SK234-253 
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Fig. 3. Dose-dependent inhibition of plasmin activity by HPG binding 
peptides. A: Amidolytic activity of fixed amounts of HPN (0.4 pM) was 
measured in the presence of varying concentrations of synthetic SK pep- 
tides (0-50 pM). and the percent survival of HPN activity was then quan- 
titated. Different reactions contained either 33234-253 (open triangles), 
SK254-273 (closed triangles), or SK274-293 (closed circles). B: Effect of 
SK and SK peptides on the kinetic parameters of HPN for amidolysis of 
G-P-L-pNA. SK (closed circles) (0.12 pM), SK143-293 (open circles) 
(0.5 pM). and SK peptides (80 p M )  viz., SK234-253 (open squares) and 
SK274-293 (closed inverted triangles), were incubated with HPN and the 
amidolytic activity in the presence of varying concentrations of G-P-L- 
pNA (0.06-0.5 mM) were then estimated. Lineweaver-Burke plots of the 
data are shown. HPN alone (closed triangles) was taken as control. 
or SK274-293, the K ,  value of HPN for its amidolytic substrate 
was increased nearly fivefold (from approximately 0.2 mM to 
1 .O mM) relative to free  HPN, with little detectable change  in Vmm. 
This property, i.e., little or no alteration of the V,, values, but a 
significant increase in K,, was comparable to that observed with 
D. Nihalani et al. 
SK as well as  the truncated fragment SK143-293. Thus, in terms 
of the property of K,  alteration, the segments SK234-253 and 
SK274-293 could mimic completely the native, full-length pro- 
tein. It should be mentioned here that the inhibitory effect was not 
due  to a competition by the peptides with the amidolytic substrate 
for hydrolysis by HPN, as could be argued, particularly because 
the peptides also contained potentially HPN-sensitive Arg- and 
Lys-containing peptide bonds. However, the observation that this 
effect was encountered only in the case of SK234-253 and SK274- 
293  among the 16-peptide set, many of which also contained in- 
ternal Arg and Lys peptide bonds, argued against such a possibility. 
We confirmed experimentally that this indeed was the case by 
RP-HPLC analysis of the test mixtures, which showed a complete 
absence of degradation of the peptide(s) during the duration of the 
kinetic measurements (data not shown). 
Apart from the high-affinity 1:l complexation of SK and HPG 
to form the activator complex,  another important facet of SK-HPG 
interaction is the generation of a functionality possessing affinity 
specifically for "substrate" PC, a property that might be imparted 
by a region, or regions, in the SK moiety in the complex. This, 
indeed, could be responsible for the (transient) formation of a 
ternary complex between SK-HPG and substrate PC, envisioned as 
a key intermediate in the catalytic conversion of PC  to PN by the 
activator complex. Once  the region playing a dominant role in 1: 1 
SK-HPG complexation was localized in and around residues 230- 
290, we were tempted to explore whether the putative substrate PG 
recognition property could also be detected in any of these core 
segments. To test this possibility, the regular PC activator assay, 
where a high concentration of substrate PC (> 1 pM) is employed 
normally, was modified to contain relatively lower amounts of 
substrate PC (0.06 pM), and the time of activation was extended 
(see Materials and methods for details) so that the assay could 
become sensitive to even low degrees of inhibition of the activa- 
tion of substrate PC (by a fixed quantity of pre-formed 1:l SK- 
HPG complex) by any fragment competing with the interaction of 
the complex with substrate PC. Besides HPG as the substrate, this 
assay was also performed with BPG because it is not activated by 
SK alone, but only by the SK-HPG or SK-HPN activator com- 
plexes, thus becoming an optimal substrate for the measurement of 
SK-HPG activator activity (Radek  et al., 1993). Before testing the 
synthetic peptides, however, we wanted to evaluate the validity of 
this approach by testing if the fragment SK143-293 showed any 
ability to selectively inhibit substrate PC activation by the pre- 
formed SK-HPG complex. Remarkably, SK143-293 could easily 
inhibit the activation of substrate BPG in a concentration-dependent 
manner [50% inhibition (IC5o) at approximately 1.2 pM]. We next 
tested each of the 16 peptides representing the region SK134-302 
in the above assay up to a maximum concentration of 300 pM. 
However, of these, only SK254-273 was found to inhibit signifi- 
cantly the activation of BPG by activator complex (ICs0 = ap- 
proximately 65 pM), with one other peptide (SK274-293) showing 
relatively marginal inhibition (Fig.  4A). In order to further explore 
the basis of this inhibition, the steady-state kinetic parameters for 
the activation of BPG by SK-HPG were also determined in the 
presence of inhibitory concentrations of SK254-273 and SK143- 
293. Whereas no significant change was observed in the values of 
kc,, for BPG activation in both cases (around 3.8 min"/ng of 
SK-HPG used), the values of K ,  in the presence of SK143-293 
and SK254-273 were increased significantly (approximately to 
0.82 pM) compared with uninhibited controls (around 0.2 pM) 
(Fig. 4B, inset). This indicated clearly that it was the apparent 
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Fig. 4. Inhibition by SK254-273 of “substrate” PG activation by the pre-formed activator complex. A: Fixed amounts of pre-formed 
equimolar complex of SK and HPG (20 nM each) were added to BPG (1 p M )  in assay buffer containing chromogenic substrate as well 
as varying concentrations of different SK peptides (0-300 pM). Plasmin activity generated was then measured spectrophotometrically. 
Different reactions contained either SK143-293 (closed squares), SK254-273 (closed circles),  83234-253 (closed inverted triangles), 
SK274-293 (open inverted triangles), or SK283-302 (open squares). Percent inhibition was calculated from the rates of plasmin 
activation in the presence of the peptides compared with those in controls (taken as 100%) without any peptide. B: Reversal of the 
inhibition of activator activity of SK-HPG by SK254-273 (closed circles) and SK143-293 (open triangles) in the presence of 
increasing concentrations of BPG. Percent activity represents the increase in substrate PG activating activity with increase in BPG 
concentration relative to the corresponding control reaction (100%) in which no peptide/fragment had been added. Inset: Lineweaver- 
Burke plot for the determination of kinetic parameters for BPG activation by SK-HPG complex in the presence of SK peptides. The 
experiment was performed under conditions identical to those mentioned above, except that the concentration of BPG was varied from 
0.035 to 3 p M  in the reaction. The control reaction where no peptide was added is depicted with closed circles, whereas reactions where 
either SK254-273 or SK143-293 was included are shown as open triangles and closed triangles, respectively. 
affinity of activator complex for hydrolysis of BPG that was af- 
fected in the presence of the peptide. Indeed, this conclusion, that 
there was direct competition between SK254-273 and SK-HPG 
for binding with substrate PC, was validated when the reversal of 
inhibition of substrate PC activation by a given concentration of 
SK254-273 could be achieved by simply increasing the concen- 
tration of BPG in the reaction (Fig. 4B). 
Discussion 
At least two qualitatively distinct types of SK-PC interactions can 
be envisioned in the generation of PG activator capability by SK 
and HPG: (1) the intermolecular, high-affinity interactions be- 
tween SK and HPG to form the 1:l molar SK-HPG activator 
complex, and (2) the transient binding of the SK-HPG activator 
complex with substrate PC molecules (ternary complex) during 
each catalytic cycle of PC activation. Precise information on the 
exact location and nature of these PC binding site(s) in SK has not 
been obtained until now. As a first step toward this goal, we chose 
to focus on the relatively short fragment, namely SK143-293, 
which showed both HPG binding and low but intrinsic PC acti- 
vator activity. In order to identify a minimal-length PC interacting 
unit (or units, if more than one locus for interaction with PC is 
involved), we employed short synthetic peptides that spanned  the 
complete length of this fragment viz., residues 134-302, to probe 
the PC-interacting functions  in this region of the molecule. Even 
though it is well-recognised that short peptides generally possess 
overall disordered structures in solution even when these are de- 
rived from stably folded segments of native proteins, such frag- 
ments display sufficient propensity to adopt their original native- 
like formats, allowing the “peptide walking” approach to be 
exploited for deciphering protein-protein interactions in diverse 
systems (Joseph & Pick, 1995; Bayley et al., 1996; Mohri et al., 
1996). In our study, too, this approach could be used successfully 
to demonstrate the direct involvement of an approximately 60- 
residue region in SK (SK230-290) that is involved in both binding 
with HPG to form the equimolar SK-HPG activator complex, as 
well as in the interaction of this activator complex with substrate 
PC. The results also indicate that the region in HPG where this 
binding takes place is probably in the close vicinity of the active 
site of HPG/HPN. 
The complexation of SK with free HPN is manifested in overall 
reduced accessibility for the active site of the latter by small mo- 
lecular weight substrates and inhibitors probably as a result of the 
binding of SK in this region (Wohl, 1984; Dawson et al., 1994). 
For example, the altered behavior of the SK-HPN complex com- 
pared with that of uncomplexed HPN is reflected in altered kinet- 
ics of amidolysis of chromogenic substrates, such as a significant 
increase in the K,  of the SK-HPN complex compared with that of 
HPN alone (Wohl et al., 1980; Robbins et al., 1981). Likewise, the 
complexation of SK with HPG results in a measurable change in 
the kinetics of binding of inhibitors at the cryptic active site of the 
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zymogen (Wohl, 1984). One reasonable explanation for these phe- 
nomena is that the binding of SK  occurs  in  the close vicinity of the 
active site region, thus creating steric hindrance for the substrate or 
ligand. Our results on the increased K ,  for amidolysis by HPN in 
the presence of the HPG binding peptides derived from the seg- 
ment 234-293  of SK indicate that the  core residues of this region 
also bind in the close vicinity of the active site. Because essentially 
the same results were observed with either SK or its truncated 
fragment, SK143-293, the inescapable conclusion that follows from 
this is that the binding of epitope(s) formed by the residues 234- 
254 and 274-293 of SK with HPN must occur  at or near the active 
site, and this affects the accessibility of the active site for the 
amidolytic substrate. Thus,  even though none of the short peptides 
was capable of promoting any detectable PC activation, with re- 
spect to at least this basal property (binding at or near the active 
site), two peptides could mimic the full-length native molecule 
with virtually complete fidelity. At the same time, the inability of 
the intervening segment viz., the peptide SK254-273, to inhibit the 
amidolytic activity suggests that this segment, in the SK-HPG 
activator complex,  is  either quite flexible or oriented in a manner 
that does not constrain access of the substrate to the active site 
sterically. 
The presence of a strong inhibitory effect of SK234-253, SK254- 
273, and SK274-293 on SK-HPG complexation prompted us to 
examine if these [or indeed any other peptide(s) from the complete 
set] could selectively inhibit the activation of substrate PC by 
activator complex as well. Experiments to explore this possibility 
demonstrated clearly that only the peptide SK254-273 could in- 
hibit the activation of either BPG or HPG by the pre-formed ac- 
tivator complex in a concentration-dependent manner. A kinetic 
analysis of the inhibition of HPG/BPG activation reaction by 
SK254-273 revealed that, whereas the V,, for PC activation was 
essentially unaffected, the K ,  values were increased significantly 
in comparison to uninhibited control reactions. Entirely in keeping 
with this observation, the inhibitory effect at a given peptide level 
could be reversed by merely increasing the concentration of sub- 
strate PC in the reaction. Thus, the enhancement in the K ,  values 
for plasminogen activation by SK-HPG  in the presence of SK254- 
273  is  due to a direct competition between the inhibitory peptide 
and the corresponding sequence in the SK-HPG complex for in- 
teraction with the substrate. When these results are gauged to- 
gether with the findings on  the ability of SK234-253 and SK274- 
293 to inhibit the formation of the SK-HPG complex, one concludes 
that this core region consists of epitopes/structural units in SK that 
(1) occupy a position at the interface of the SK-HPG complex and 
(2) are also proximal to the protease active site in the SK-HPG 
complex. The segment SK254-273 in this core could then tran- 
siently attach to substrate PC during the catalytic cycle of PC 
activation by the 1 : 1 SK-HPG  complex,  and so impart the highly 
characteristic substrate-discrimination property into the SK-HPG 
complex by positioning the substrate in the proper orientation for 
cleavage at  the scissile peptide bond. The present study thus offers 
tantalizing evidence for the first time that a stretch of residues in 
the core region of SK that is involved in tight binding near the 
active site of HPG/HPN itself contributes to the generation of this 
intriguing but fundamental functionality in the activator complex. 
With the localization of the core sequences involved in interacting 
with PC  to a relatively small segment of primary structure in  SK, 
several powerful experimental approaches, including site-directed 
mutagenesis, can now be applied in concert toward understanding 
the molecular basis of SK action with greater precision. It should 
be recognized, however, that regions in SK other than the core 
region identified in our study also contribute to the generation of 
full-blown activator activity, first in the initial SK-HPG virgin 
enzyme complex, and, subsequently, in the SK-HPN complex 
(Young et al., 1995). This  is exemplified clearly by the observation 
that the fragment SK143-293, which contains the core region re- 
sponsible for both HPG binding during activator complex forma- 
tion as well as substrate recognition by pre-formed complex, is 
weakly active at best. The fact that SK1-59, which encompasses 
an additional HPG binding site but, by itself, is inactive (Shi et al., 
1994; Nihalani & Sahni, 1995; Parrado et al., 1996), can consid- 
erably enhance the low activity of SK143-293, highlights strongly 
the role of the N-terminal region of SK in the attainment and/or 
maintenance of a proper native-like fold in the core region (Young 
et al., 1995; Parrado et al., 1996). Studies aimed at understanding 
the mechanism of the complementation of the low intrinsic activity 
of SK fragments derived from the central portion of the molecule 
by synthetic peptides based on the N-terminal region, in concert 
with site-specific mutagenesis of residues of the core region, should 
now be helpful in revealing the mechanism of SK action with 
greater clarity. 
Materials  and  methods 
Reagents 
Glu-plasminogen was purified from human plasma by affinity chro- 
matography (Deutsch & Mertz, 1970) (>98% Glu-form as deter- 
mined by N-terminal amino acid sequencing), or obtained from 
Boehringer-Mannheim. Conversion of HPG to HPN was per- 
formed by treatment with immobilized UK (100 Plough units/mg 
of HPG; UK was immobilized on cyanogen bromide activated 
Sepharose 4B). Highly pure, albumin-free SK from Streptococcus 
equisimilis (strain H46 A) was a kind gift from Dr. D. Gerlach 
(Jena, Germany) and Dr. R.A.G. Smith (Smith-Kline Beecham, 
UK). Both preparations showed single bands by SDS-PAGE, and 
displayed specific activities of 110,000-120,000 I.U./mg protein 
(Bradford,  1976; Jackson et al., 1981). Antisera to HPG was raised 
in rabbits and their titers determined by dot blot as well as ELISA. 
All other reagents used were of the highest purity commercially 
available. 
Preparation and characterization of tryptic fragments of SK 
Tryptic fragments of SK, namely SK1-59, SK60-293, and SK143- 
293, were prepared as described previously (Nihalani & Sahni, 
1995). The individual fragments were cross-checked for heteroge- 
neity as well as the possible presence of any residual undigested 
SK by rechromatography on a narrow-bore C-4 column (2 X 
100  mm; Brownlee) (gradient: 5”5% acetonitrile [ACN] contain- 
ing 0.1% trifluoroacetic acid [TFA] over  120 min at a flow rate of 
80 pL/min). The HPLC work was performed on a Perkin Elmer- 
Applied Biosystems model 172 microbore HPLC system. Control 
“spiking” experiments showed that even trace quantities of SK 
could be detected under these conditions of chromatography, which 
eluted at a position distinctly resolved from either SK60-293 or 
SK143-293 (data not shown). Moreover, the kinetic parameters of 
these fragments were found to be quite different from that of SK 
(four- to fivefold increase in K,  for HPG activation and approxi- 
mately 1,000-fold decrease in V,,), which remained unaltered 
upon rechromatography. Also the kinetic characteristics of  SK sub- 
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jected to RP-HPLC under these conditions were found to be un- approximately 20-30% solubility was achieved. However, upon 
altered, indicating that the low activities of these fragments are not reversal to assay conditions by dilution in buffer of near-neutral 
due to denaturation brought about by the isolation procedure. SK pH, precipitation was found to reoccur. 
fragments were characterized by N-terminal sequence analyses 
and ion-spray mass spectroscopy, and quantitated by amino acid 
analysis after PITC derivatization (Findlay & Geisow, 1989). Ly- 
ophilized polypeptide fragments were stored desiccated at - 20 "C 
Assay for the generation of amidolytic activity 
in peptide-HPG mixtures 
in the  dark until reconstituted just prior to use. 
Assays for studying  the activation of  HPG 
by SK and SK fragments 
HPG (final concentration 4.0 p M )  was incubated with 80 p M  each 
of HPG binding peptides at 22 "C for 10 min. Amidolytic activity 
was determined by adding a suitable aliquot of the complex to an 
assay cuvette containing assay buffer in a final volume of 100 pL. 
The  change in absorbance at 405 nm was monitored as previously. 
A one-stage assay method was used to measure the kinetics of Complexes of HPG with SK, SK143-293, and HPG nonbinding 
HPG activation by SK or its truncated fragments (Wohl et al., 
1980;  Shi  et al., 1994). SK (0.5 nM) or individual fragments, viz., 
SK60-293 (0.2 pM), SK143-293 (0.4 pM), or SK1-59 (1 pM), 
were reconstituted freshly from the stored state in 50 mM Tris-C1 
buffer, pH 7.5, and added to 100 pL-assay cuvette containing HPG 
(4 pM) in assay buffer [50 mh4 Tris-CI buffer, pH 7.5, also con- 
taining 0.5 mM chromogenic substrate (tosyl-Gly-Pro-Lys-pNA, 
obtained from Sigma) and 0.1 M NaCI]. The change in absorbance 
was then measured as a function of time in a Shimadzu UV-160 
peptides were taken as controls. Competition assays were per- 
formed to determine the effect of HPG binding peptides on the 
creation of an active site in HPG by SK. Various concentrations of 
peptides (0-300 p M )  were incubated with HPG in 50 mM Tris-C1 
buffer, pH 7.5, at 22 "C for 5 min. The mixture was then added to 
the assay cuvette containing assay buffer and SK. The  final  con- 
centrations of SK and HPG in the reaction mixture were 10 nM 
and 8 nM, respectively. Change in absorbance was measured at 
405 nm for 15 min at 22°C. Assay where no  SK or peptide was 
model spectrophotometer at  22 "C. added was taken as control. 
Generation of amidolytic activity in HPG by SK60-293 Amidase parameters of HPN in  the presence 
and SK143-293 in the presence of SKI-59 of SK, SK fragments, and SK peptides 
Fragment SK1-59  (0.1-0.8 p M )  was added to 0.2 pM of either The generation of activator activity in peptide-HPN mixtures was 
SK60-293 or SK143-293 and incubated at 22°C for 5 min. The determined by incubating 80 p M  peptide with 0.4 p M  HPN in 
mixture was then added to the assay cuvette containing assay Tris-C1 buffer, pH 7.5, containing 0.5% (w/v) BSA at 22°C for 
buffer and 4.0 p M  HPG. Generation of amidolytic activity was 10 min. BPG (2.5 p M  final concentration) was then added to the 
observed by recording change in absorbance at 405 nm as de- reaction mixture and BPN activity was measured as described 
scribed previously. In control reactions, the activity of either SK1-59 previously. Reactions where no BPG was added to the complex 
alone, or in the presence of SK, was also measured. Under these (peptide-HPN), or with HPN alone (with no  peptide  added), were 
conditions, SK1-59 did not show any detectable activity up to a taken as controls. Kinetic parameters for the HPN (amidolytic) 
concentration of 1 pM, nor  did  it enhance the activity of SK. activity in the presence of SK (0.12 pM), SK fragment (0.5 pM), 
or SK peptides (80 pM) were determined by incubating them with 
0.1 p M  HPN in 50 mM Tris-C1 buffer, pH  7.5, containing 0.5% 
(w/v) BSA at 22°C for 5 min. Aliquots from these mixtures were 
then added to assay cuvettes containing various concentrations of 
G-P-LpNA in Tris-C1 buffer, pH 7.5, ranging from 0.06 mM to 
Exploration of  the HPG  binding  region (SK134-302) 
using synthetic peptides for identification 
of sequences involved in  HPG binding 
A set of 16 overlapping peptides corresponding to the sequence 0.5 mM. The change in absorbance was monitored spectrophoto- 
134-302 of SK (Malke et al., 1985), containing 20 amino acid metrically at 405 nm for 10 min. In the control reaction, no SK, SK 
residues each, were synthesized by Chiron Mimotopes, Australia. fragments, or SK peptides were added. 
The punty of each peptide was then established through ion-spray 
-~ 
mass spectrometry on a Perkin-Elmer Sciex I1 spectrometer and 
RP-HPLC. Qualitative analysis of binding of each peptide to HPG 
was determined by a dot blot assay established earlier to be a 
Assay for determining inhibition of  PG activator activity 
of pre-formed SK-HPG complex by  peptides 
sensitive index of PG binding by SK or its proteolytically trun- The SK-HPG activator complex was formed by pre-incubating 
cated products (Nihalani & Sahni, 1995). This involved, briefly, equimolar concentrations (20 nM each) of SK and HPG in a total 
the adsorption of each peptide onto nitrocellulose sheet, and then volume of 50 p L  containing 50 mM Tris-C1 buffer, pH 7.5, and 
probing with '251-labeled HPG. Quantitative binding of each pep- 0.5% BSA at  22 "C for 2 min (Radek  et al., 1993). A 10-pL aliquot 
tide to HPG was performed through an ELISA using polyclonal from this reaction mixture was then added to a spectrophotometric 
HPG-specific antiserum, as described previously (Nihalani & Sahni, cuvette (100-pL capacity) containing various concentrations of 
1995). The relative binding affinities of HPG binding peptides individual peptides (0-300 pM) in assay buffer and also 0.06 p M  
with reference to SK were computed through noncompetitive ELISA of either BPG or HPG in a total volume of 100 pL. After rapid 
(Beatty et al., 1987). HPG binding of one of the SK peptides, mixing, the generation of amidolytic activity was measured spec- 
SK243-262, could not be studied because of its very low solubility trophotometrically by recording the increase in rate of release of 
under the conditions of assay. Efforts were made to solubilize it p-nitroanilide  from  the chromogenic substrate over control reac- 
both at low and high pH, or by inclusion of NaCl or DMF (di- tion by the bovine or human plasmin generated as a result of BPG 
methyl formamide); indeed, with some of the above conditions, or HPG activation for a period of 10 min at 22°C. The control 
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reaction, to measure the basal activity of the activator complex, 
contained all components except the test peptide. The extent of 
inhibition of activator activity by different concentrations of a 
given peptide was then determined and expressed in percentage 
relative to control reactions (taken as 100%) conducted in the 
absence of peptide. For the determination of kinetic parameters of 
BPG/HPG activation by the pre-formed activator complex, the 1: 1 
SK-HPG complex was formed under identical conditions as de- 
scribed above and a similar aliquot was added to the assay cuvette 
containing 50 pM concentration of peptide SK254-273 or 1 pM 
of 143-293 and varying concentrations of either BPG or HPG 
(0.035-3 p M )  in assay buffer and the amidolysis was observed for 
5 min at 22 “C. In the  control reaction, no peptide was added. The 
inhibition of substrate PG activation brought about by the peptide 
(using a fixed concentration that resulted in approximately 50% 
inhibition in the reactions when 0.5 JAM concentration of BPG/ 
HPG was used)  was relieved by using various increasing concen- 
trations (0-3 p M )  of BPG/HPG in the above reaction. The kinetic 
parameters for BPG/HPG activation, K,,, (the apparent Michaelis 
constant for PG as substrate) and kc,, (the catalytic rate constant of 
activation), were calculated by standard methods (Wohl et al., 
1980). 
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